What is Knee Replacement in America?
Knee replacement surgery — medically known as total knee arthroplasty (TKA) — is one of the most commonly performed orthopedic procedures in the United States today. The surgery involves removing damaged cartilage and bone from the knee joint and replacing it with an artificial implant made of metal alloys, high-grade plastics, and polymers. It is primarily performed on patients suffering from severe knee osteoarthritis, rheumatoid arthritis, or post-traumatic arthritis, where conservative treatments such as physical therapy, medications, and injections have failed to provide adequate relief. Over 700,000 Americans undergo total knee replacement every single year, according to the American Academy of Orthopaedic Surgeons (AAOS), making it a cornerstone of modern orthopedic care in this country.
What makes knee replacement in the US in 2026 especially significant is how dramatically the landscape has shifted in recent years. Patients who once faced multi-day hospital stays now often go home the same day. Robotic-assisted surgical systems, enhanced recovery protocols, and outpatient ambulatory surgery centers have fundamentally changed who gets this surgery, how it’s done, and what recovery looks like. With 32.5 million US adults suffering from knee osteoarthritis — the number one driver of knee replacement demand — and an aging Baby Boomer population pushing surgical volumes higher each year, understanding the latest knee replacement statistics for 2026 is more important than ever for patients, caregivers, and healthcare planners alike.
Interesting Facts About Knee Replacement in the US 2026
KNEE REPLACEMENT FAST FACTS — US 2026
========================================
Annual Procedures ████████████████████ ~700,000+
Implant Success@15yr ████████████████████ 90%+
Female Patients ████████████████ ~62–63%
Outpatient Share █████████████ 27–50%+
Robotic Use (2023) ████ 15.9%
Revision Rate@10yr ██ ~2.13%
Pain Relief Success ████████████████████ 90–95%
Scale: Each █ ≈ 5 percentage points or proportional units
| Fact | Statistic / Detail |
|---|---|
| Annual knee replacements in the US | Approximately 700,000+ total knee replacements performed per year (AAOS) |
| US adults with osteoarthritis (leading cause) | 32.5 million US adults have osteoarthritis; 53.2 million have some form of arthritis (CDC) |
| Adults aged 45+ with knee OA | Up to 30% of US adults aged 45 or older have knee osteoarthritis (Cureus, 2024) |
| Arthritis prevalence in US adults (2024) | 21.3% of US adults age 18+ have diagnosed arthritis (CDC NHIS, 2024) |
| Gender split among knee replacement patients | Approximately 62–63% female, 37–38% male |
| Average age of knee replacement patient | Mean age of approximately 68 years |
| Implant survival at 15 years | Over 90% of knee replacements still functioning at 15 years (AAOS) |
| Implant survival at 25 years | ~82% of total knee replacements still functioning at 25 years (pooled registry data) |
| 10-year revision rate (cemented TKA) | 2.13% — from the 2023 AJRR Annual Report |
| Most common reason for revision TKA (2023) | Infection — responsible for 32.5% of all revision total knee arthroplasties (AJRR 2024 Report) |
| Robotic-assisted TKA usage | 15.9% of primary TKA procedures in 2023 — an 8-fold increase since 2017 (AJRR 2024 Report) |
| Projected robotic TKA share by 2030 | Estimated to reach 70.1% of all TKA procedures by 2030 |
| Outpatient / ASC procedures (2024) | Over 27% of US knee replacements now performed in ambulatory surgery centers |
| Average total cost of knee replacement | Approximately $19,500–$29,300 depending on facility and complexity |
| Medicare Part A inpatient deductible (2025) | $1,676 per benefit period |
| Medicare Part B annual deductible (2025) | $257 per year; covers 80% of approved amounts after deductible |
| Revision TKA procedures in 2019 (baseline) | 53,217 revision TKAs — projected to grow at 4.67% annually (CMS/Medicare data, Arthroplasty Today, 2023) |
| Projected revision TKA by 2040 | Estimated 115,147 revision knee procedures (CMS Medicare projections) |
| Projected primary TKA by 2025 | ~1.272 million procedures projected (Journal of Rheumatology modeling) |
| Women lifetime OA risk | 47% of women will develop osteoarthritis vs. 40% of men (Cureus, 2024) |
Source: CDC NHIS 2024; AAOS / AJRR 2024 Annual Report; CMS Medicare Data; Arthroplasty Today (June 2023); Journal of Rheumatology; Osteoarthritis Action Alliance
The sheer scale of knee replacement surgery in America is hard to overstate. With well over 700,000 procedures performed annually, the US performs more total knee replacements per capita than virtually any other nation on earth. What stands out most from the facts above is the combination of high surgical volume and remarkably strong long-term outcomes — over 90% of implants continue to function well at the 15-year mark, which directly explains why patients and surgeons alike have such strong confidence in this procedure. The data from the CDC confirming that 21.3% of US adults have diagnosed arthritis as of 2024, combined with the reality that up to 30% of adults aged 45+ have knee osteoarthritis specifically, makes clear that the pool of potential candidates for this surgery will only grow in coming decades.
The demographic profile of the average knee replacement patient tells its own important story. Women represent roughly 62–63% of all patients, reflecting both the higher lifetime risk of osteoarthritis in women (47% vs. 40% for men) and the fact that women tend to seek care for chronic joint conditions at higher rates. The mean age of approximately 68 years speaks to the reality that Medicare is the dominant payer for this surgery — a fact confirmed by payer data showing Medicare covering roughly 60% of all knee replacement hospitalizations. Perhaps the most forward-looking number in the table is the projected 70.1% robotic-assisted share by 2030, which signals that the surgical experience for knee replacement patients is on the cusp of a fundamental technological transformation within just a few years.
Knee Replacement Procedure Volume & Projections in US 2026
ANNUAL TKA PROCEDURE VOLUME TRENDS & PROJECTIONS — US
=======================================================
2000 |████ ~200,000
2007 |██████████████ ~700,000
2020 |████████████████████ ~1,065,000 (projected)
2025 |████████████████████████████ ~1,272,000 (projected)
2030 |█████████████████████████████████ ~1,921,000 (projected)
2040 |████████████████████████████████████████████ ~3,416,000 (projected)
Source: Journal of Rheumatology (NIS + Census Bureau modeling)
Scale: Each █ ≈ ~80,000 procedures
| Year | Estimated / Projected Annual TKA Procedures (US) | Notes |
|---|---|---|
| 2000 | ~200,000 | HCUP/NCHS National Hospital Discharge Survey baseline |
| 2007 | ~700,000 | HCUP data; TKA most frequent inpatient surgery for adults 45+ |
| 2010 | ~719,000 | NIS data; peak pre-ACA inpatient volume |
| 2014 | Baseline for projections | National Inpatient Sample (NIS) reference year |
| 2020 | ~1,065,000 (projected) | Journal of Rheumatology NIS-based model |
| 2025 | ~1,272,000 (projected) | 95% PI: 1,200,000–1,710,000 |
| 2030 | ~1,921,000 (projected) | 95% PI: 1,530,000–2,410,000 |
| 2040 | ~3,416,000 (projected) | 95% PI: 2,459,000–4,745,000 (401% increase vs. 2014) |
Source: Journal of Rheumatology (NIS + US Census Bureau projections, published data); HCUP / AHRQ National Hospital Discharge Survey; AAOS
The trajectory of total knee replacement volume in the United States is nothing short of remarkable. From roughly 200,000 procedures per year in 2000, the number climbed to approximately 700,000 by 2007 — a more than threefold increase in just seven years — driven by the expanding use of the procedure in younger and more active patient populations, as well as better implant technology and broader insurance coverage. The projection models built from the National Inpatient Sample data and US Census Bureau population estimates paint an even more dramatic picture for the decades ahead. By 2025, annual TKA volumes are projected to reach roughly 1.27 million procedures, and by 2040, that number could climb to approximately 3.4 million — representing a 401% increase compared to 2014 baseline figures.
What makes these projections particularly credible is the underlying demographic mathematics driving them. The US population is aging rapidly, and the 65-and-older cohort — the single highest-risk group for knee osteoarthritis and the demographic most likely to receive knee replacement surgery — is expanding dramatically as the Baby Boomer generation moves through its 70s and 80s. At the same time, surgeons have become significantly more willing to perform knee replacement in younger patients, with the 45–64 age group seeing a 188% increase in procedure rates during the 2000–2010 decade alone. The healthcare system will need to scale significantly in terms of surgeon training, operating room capacity, and rehabilitation infrastructure to meet this rising demand for knee replacement surgery in the US through 2026 and beyond.
Knee Replacement Costs & Insurance Coverage in US 2026
AVERAGE KNEE REPLACEMENT COST BREAKDOWN — US 2026
===================================================
Hospital Facility Fee ██████████████████████████ $15,000–$40,000
Surgeon Fee (Medicare) ██ ~$977 (weighted avg.)
Anesthesia ████ ~$1,500–$3,000
Implant / Hardware ██████████ ~$5,000–$10,000
Pre/Post-Op Care ████ ~$2,000–$5,000
Rehab / PT ████ ~$2,000–$5,000
-----------------------------------------------------------------
TOTAL (No Insurance) ████████████████████████████████ $30,000–$60,000
Out-of-Pocket w/ Medicare ██ ~$2,000–$8,000
Scale: Each █ ≈ ~$2,000
| Cost Category | Amount / Range (US 2026) | Coverage Notes |
|---|---|---|
| Average total cost (no insurance) | $30,000–$45,000 (before discounts) | Varies by hospital, region, complexity |
| Commercial insurance total bill range | $30,000–$60,000 (billed amount) | In-network out-of-pocket: ~$2,500–$7,500 |
| Average total cost cited in research | ~$19,500–$29,300 | Journal of Orthopaedic Surgery and Research |
| Out-of-pocket with Medicare (typical) | $2,000–$8,000 | Depends on plan, stay length, rehab needs |
| Medicare Part A inpatient deductible (2025) | $1,676 per benefit period | Covers hospital stay (full for first 60 days) |
| Medicare Part B annual deductible (2025) | $257 per year | Covers 80% of approved outpatient charges |
| Medicare surgeon payment (weighted avg.) | ~$977 | Hospital/facility fee billed separately |
| Medicare Part C (Advantage) avg. premium (2026) | ~$14/month (down from $17 in 2025) | Coverage mirrors Original Medicare + extras |
| Medicare physical therapy cap (2026) | $2,480/year for PT; $2,480 separately for OT | Doctor must confirm necessity beyond cap |
| Outpatient (ASC) vs. inpatient cost savings | ASC saves $15,000–$30,000 vs. inpatient | Per Norton Healthcare reporting |
| Partial knee replacement (PKR) avg. outpatient | ~$19,002 vs. $30,249 inpatient (BCBS 2019 data) | PKR generally less than TKR |
Source: CMS Medicare Provider Utilization & Payment Data; Centers for Medicare & Medicaid Services (CMS) 2025–2026 Coverage Data; Journal of Orthopaedic Surgery and Research
The cost of knee replacement surgery in the United States in 2026 remains one of the most significant financial considerations for patients and their families. At the uninsured or out-of-network level, total bills can range anywhere from $30,000 to over $60,000 when hospital facility fees, surgeon charges, anesthesia, the implant hardware itself, and post-operative rehabilitation are all factored in. However, for the majority of patients — who are covered by either Medicare or commercial insurance — the real out-of-pocket cost picture is considerably more manageable. Medicare beneficiaries typically face between $2,000 and $8,000 in actual out-of-pocket spending, while privately insured patients commonly land in the $2,500–$7,500 range after deductibles and coinsurance.
One of the most consequential financial shifts happening right now in knee replacement care in the US is the accelerating move to outpatient ambulatory surgery centers. As of 2024, over 27% of all US knee replacements are being performed in ASCs — a figure that continues to climb — and this shift translates into real savings of $15,000–$30,000 per procedure compared to traditional inpatient hospital stays. For Medicare beneficiaries in 2026, the coverage framework remains built around Part A for inpatient stays (with a $1,676 deductible) and Part B for outpatient procedures and surgeon fees (covering 80% after the $257 annual deductible). The average Medicare Advantage premium has dropped to approximately $14/month for 2026, making these plans increasingly attractive for seniors planning elective joint surgery.
Knee Replacement Recovery Timeline & Outcomes in US 2026
TYPICAL KNEE REPLACEMENT RECOVERY MILESTONES — US 2026
=======================================================
Surgery Day |█ Same-day discharge possible (ASC/outpatient)
Week 1–2 |████ Walking with assist; PT begins immediately
Week 4–6 |████████ Independent walking; stairs with rail
Month 3 |████████████ Return to most daily activities
Month 6 |████████████████ Near-full function restored
Month 12 |████████████████████ Full recovery benchmark
Year 15+ |████████████████████ 90%+ implants still functioning
Year 25 |████████████████████ ~82% still functioning
Key: █ = milestone progress; more █ = greater recovery level
| Recovery Milestone | Typical Timeframe / Outcome (US 2026) |
|---|---|
| Hospital / facility discharge | Same day (outpatient ASC) or 1–3 days inpatient |
| Walking with assistance begins | Day 1–2 post-surgery under physical therapist guidance |
| Return to light daily activities | 3–6 weeks post-surgery |
| Return to driving | 4–6 weeks (left knee sooner; right knee depends on state/surgeon) |
| Return to most normal activities | 3 months post-surgery |
| Full functional recovery benchmark | 12 months — most patients at near-full capacity |
| Pain relief success rate | 90–95% of patients report significant pain reduction |
| Implant survival at 15 years | Over 90% still functioning (AAOS) |
| Implant survival at 20 years | ~90.8% survival rate for revision due to any reason (NIH/NCBI, 2024 study) |
| Implant survival at 25 years (TKR, registry data) | ~82.3% (pooled registry data, Lancet meta-analysis) |
| Serious complication rate | ~2 in 100 patients experience a severe complication (AAOS) |
| Periprosthetic infection rate | Less than 1% (modern antibiotic protocols; American Association of Hip and Knee Surgeons) |
| 10-year revision rate (cemented TKA) | 2.13% (AJRR 2023 Annual Report) |
| Most common revision reason (2023) | Infection — 32.5% of all revision TKAs (AJRR 2024 Report) |
| Robotic-assisted TKA hospital stay reduction | Nearly half a day shorter vs. manual surgery (Archives of Orthopaedic and Trauma Surgery, 2024) |
Source: AAOS / American Association of Hip and Knee Surgeons; AJRR 2024 Annual Report (CMS/AAOS); NIH/NCBI Arthroplasty studies; Archives of Orthopaedic and Trauma Surgery (2024)
The recovery experience from knee replacement surgery in the US in 2026 has been fundamentally transformed by advances in surgical technique, anesthesia, and post-operative rehabilitation protocols. Patients who undergo surgery in outpatient ambulatory surgery centers often go home the same day, and under Enhanced Recovery After Surgery (ERAS) protocols, walking with assistance typically begins within the first 24–48 hours of surgery. The majority of patients return to light daily activities within 3–6 weeks and reach a functional recovery benchmark — meaning near-full capacity for most activities of daily living — within 12 months of surgery. Most strikingly, 90–95% of patients report significant or complete pain relief, which is the primary reason patients elect to have the surgery in the first place.
From a long-term outcomes perspective, the data on knee replacement implant survival is consistently reassuring. The AAOS confirms that over 90% of implants are still functioning at 15 years, and pooled registry data puts the 25-year survival rate at approximately 82.3% for total knee replacements. The 10-year revision rate for cemented TKA — the most common type — stands at just 2.13% per the AJRR’s 2023 data, meaning the overwhelming majority of patients never need a second surgery on the same joint. When revisions are needed, infection now accounts for the largest share (32.5% in 2023), reflecting progress in addressing mechanical failure as implant engineering has improved. Robotic-assisted approaches, which now account for nearly 16% of primary TKAs, are demonstrating shorter hospital stays and fewer complications — a trend that will only accelerate as robotic adoption grows toward the projected 70% share by 2030.
Knee Replacement Patient Demographics in US 2026
PATIENT DEMOGRAPHICS — US KNEE REPLACEMENT 2026
================================================
GENDER
Female ████████████████ ~62–63%
Male ████████████ ~37–38%
AGE GROUP (OA Prevalence — Adults 45+)
Ages 45–64 ████████████████████ Fastest growing TKA segment
Ages 65–84 ████████████████████████████ Largest volume group
Ages 85+ ████ Smaller share; higher surgical risk
PAYER MIX
Medicare ████████████████████████ ~60.8%
Private █████████████ ~32.5%
Medicaid █ ~2.6%
Other ██ ~4.1%
Scale: Each █ ≈ ~4–5 percentage points
| Demographic Category | Statistic / Data Point |
|---|---|
| Mean age at knee replacement | Approximately 68 years |
| Female patients | ~62.7% of knee replacement recipients are female |
| Male patients | ~37.3% of knee replacement recipients are male |
| Lifetime OA risk — Women | 47% of women will develop osteoarthritis (Cureus, 2024) |
| Lifetime OA risk — Men | 40% of men will develop osteoarthritis (Cureus, 2024) |
| Adults 65+ with arthritis | Nearly 50% of adults 65 and older have an arthritis diagnosis |
| OA prevalence in adults 45+ | Up to 30% have knee OA; 88% of all OA patients are 45 or older (Osteoarthritis Action Alliance, 2025) |
| Fastest-growing TKA age segment | Ages 45–64: saw a 188% increase in procedure rates from 2000–2010 (NCHS) |
| Payer — Medicare share | ~60.8% of knee replacement hospitalizations covered by Medicare |
| Payer — Private insurance | ~32.5% of knee replacement hospitalizations |
| Payer — Medicaid | ~2.6% of knee replacement hospitalizations |
| Race — White patients | ~86.9% of knee replacement patients in inpatient data |
| Race — Black patients | ~4.2% — documented racial disparity in TJR access persists (AAOS) |
| Arthritis + low income | 24.7% prevalence vs. 16.6% at 400%+ of federal poverty level (CDC NHIS 2022) |
| Adults with knee OA younger than 65 | More than half of people with symptomatic knee OA are under 65 (Osteoarthritis Action Alliance) |
Source: CDC NHIS 2022 & 2024; NCHS Data Brief No. 210 (CDC); Osteoarthritis Action Alliance 2025; Cureus 2024; AAOS published demographic data
Understanding who undergoes knee replacement surgery in the United States is essential for grasping the full scope of this healthcare challenge. Women make up the clear majority — approximately 62.7% of all patients — a disparity rooted in the biological reality that women face a 47% lifetime risk of developing osteoarthritis compared to 40% for men, and that women tend to develop more severe joint disease at earlier ages. The mean age of knee replacement recipients sits at approximately 68 years, placing the majority of procedures squarely within the Medicare-eligible population — which is why Medicare covers roughly 60.8% of all knee replacement hospitalizations in the US.
What the demographic data also makes starkly clear is that racial and socioeconomic disparities in access to knee replacement persist and remain a significant public health concern. Black patients represent only about 4.2% of knee replacement recipients despite bearing a substantial burden of osteoarthritis — a disparity that AAOS researchers have attributed to underutilization of total joint replacement in minority populations, not to differences in disease prevalence alone. Similarly, arthritis prevalence is highest among lower-income Americans — 24.7% among those below the federal poverty line — yet this group faces the greatest financial barriers to accessing surgical care. The 45–64 age bracket is simultaneously the fastest-growing demographic for knee replacement demand, having seen a 188% increase in procedure rates during 2000–2010, and the group most likely to still be in the workforce and relying on private insurance rather than Medicare.
Robotic-Assisted Knee Replacement Technology Trends in US 2026
ROBOTIC-ASSISTED TKA ADOPTION — US (% of All Primary TKAs)
============================================================
2008 | 0.01% (near zero)
2017 |█ ~2% (AJRR baseline reference)
2020 |████ ~8.5%
2022 |████████ ~12.5% (AJRR 2024 Report)
2023 |████████████ ~15.9% (AJRR 2024 Report — 8x increase from 2017)
2030* |████████████████████████████████████████████ ~70.1% (projected)
* Projected: ScienceDirect log-binomial regression model (2025)
Scale: Each █ ≈ ~4 percentage points
| Metric | Data / Statistic |
|---|---|
| Robotic-assisted TKA share in 2017 | ~1.8% of primary TKA procedures (AJRR reference baseline) |
| Robotic-assisted TKA share in 2022 | 12.5% of primary TKA procedures (AJRR 2024 Annual Report) |
| Robotic-assisted TKA share in 2023 | 15.9% of primary TKA procedures — 8-fold increase from 2017 (AJRR 2024 Annual Report) |
| Projected robotic TKA share by 2030 | 70.1% of all TKAs (95% CI: 65.5–74.5%) — ScienceDirect, 2025 modeling |
| Mako system installations worldwide (2024) | 2,000+ Stryker MAKO systems installed globally at year-end 2024 |
| MAKO robotic knee % at Stryker (2024) | Approximately 2/3 of all knee surgeries at top Stryker centers use MAKO |
| Global knee implants with MAKO (2024) | Over 45% of global knee implant procedures used MAKO robotic systems |
| ASC knee replacement share (2024) | Over 27% of US knee replacements in ambulatory surgery centers |
| Hospital stay reduction — robotic TKA | Nearly half a day shorter vs. manual TKA (Archives of Orthopaedic and Trauma Surgery, 2024) |
| Complication rates — robotic vs. manual | Robotic TKA associated with fewer infections, less blood loss, fewer dislocations/fractures |
| Computer navigation use (2023) | Declined from 5.2% in 2022 to 4.0% in 2023 as robotic adoption increases (AJRR 2024 Report) |
| Robotic procedures in 2020–2022 study (NIS/NASS) | 13,194 robotic-assisted procedures out of 85,265 total TKA/UKA cases studied |
Source: AJRR 2024 Annual Report (AAOS/CMS); ScienceDirect robotic TKA projection study (2025); Archives of Orthopaedic and Trauma Surgery (2024); Arthroplasty Today; Gabelli Orthopedics Market Report 2025
The rise of robotic-assisted knee replacement surgery in the United States is arguably the single most dramatic technological story in orthopedic surgery today. What began as a niche technology used in fewer than 2% of procedures in 2017 has grown to represent nearly 16% of all primary TKA procedures by 2023 — an 8-fold increase in just six years — and modeling published in 2025 projects that figure will reach 70.1% by 2030. The Stryker MAKO system leads the US market, with over 2,000 installations worldwide and approximately two-thirds of all knee surgeries at top Stryker-equipped centers now performed robotically. This shift is being driven not just by technology enthusiasm, but by measurable clinical outcomes — robotic-assisted patients see hospital stays that are nearly half a day shorter and experience significantly lower rates of infections, excessive blood loss, and mechanical complications compared to manual procedures.
The parallel trend driving adoption is the ongoing shift of knee replacement surgery from hospital inpatient settings to outpatient ambulatory surgery centers (ASCs). Over 27% of all US knee replacements were performed in ASCs as of 2024, and that number is rising every year. Robotic systems are increasingly being deployed in ASC settings as the technology becomes smaller, more efficient, and more cost-effective to operate. Computer navigation — once considered the high-tech alternative to manual surgery — has actually seen its usage decline from 5.2% to 4.0% between 2022 and 2023, as surgeons skip navigation and move directly to full robotic assistance instead. The combination of robotic precision, outpatient settings, and enhanced recovery protocols is redefining what knee replacement recovery looks like for Americans in 2026 — and for the generation of patients who will follow.
Revision Knee Replacement Statistics in US 2026
REVISION TKA TRENDS & PROJECTIONS — US
=======================================
2019 (Actual) |████████████████████████████ 53,217 revision TKAs
2025 (Est.) |████████████████████████████████ ~65,000–70,000 (est.)
2030 (Proj.) |█████████████████████████████████████ ~80,000+ (est.)
2040 (Proj.) |████████████████████████████████████████████████████████ 115,147
2060 (Proj.) |██████████████ (286,740 — 520% increase vs. 2019)
Annual growth rate for revision TKA: ~4.67% (CMS Medicare model)
Scale: Each █ ≈ ~5,000 procedures
| Revision TKA Metric | Statistic / Projection |
|---|---|
| Revision TKA procedures in 2019 (US baseline) | 53,217 revision total knee arthroplasties (CMS Medicare Part B data) |
| Annual growth rate for revision TKA | 4.67% per year (CMS/Medicare projection model) |
| Projected revision TKA by 2040 | 115,147 (95% forecast interval: 105,640–125,510) |
| Projected revision TKA by 2060 | 286,740 (95% forecast interval: 253,882–323,852) |
| Increase in revision TKA by 2040 vs. 2019 | +149% increase projected |
| Increase in revision TKA by 2060 vs. 2019 | +520% increase projected |
| Most common cause of revision TKA (2023) | Infection — 32.5% of all revision TKAs (AJRR 2024 Annual Report) |
| Overall 10-year revision rate (cemented TKA) | 2.13% (AJRR 2023 Annual Report) |
| TKA survival rate at 20 years (NIH data) | 96.8% survival — one large cohort study (PMC/NIH, 2025) |
| TKA survival at 4 years | 99.6% — general short-term benchmark |
| Pooled registry TKA survival at 25 years | 82.3% (95% CI: 81.3–83.2) — Lancet meta-analysis |
| UKR survival at 25 years | 72.0% (95% CI: 58.0–95.0) — lower than TKR |
| Primary payer for revision TKA | Predominantly Medicare (CMS data) |
Source: CMS Medicare Part B National Summary Data; Arthroplasty Today (Shichman et al., June 2023); AJRR 2023 & 2024 Annual Reports; PMC/NIH early revision TJA study (2025); Lancet meta-analysis on knee replacement survival
Revision knee replacement surgery — procedures that replace or repair a previously implanted knee prosthesis — represents one of the fastest-growing segments of orthopedic surgery in the United States, and the data paints a sobering picture for healthcare planners. Starting from a baseline of 53,217 revision TKA procedures in 2019, CMS Medicare modeling projects an annual growth rate of 4.67%, meaning this figure could more than double to 115,147 by 2040 and reach a staggering 286,740 by 2060 — a 520% increase within four decades. The arithmetic behind this projection is straightforward: as the cumulative number of Americans living with a knee replacement grows year over year, the absolute number of those whose implants eventually reach the end of their service life or develop complications grows in parallel.
The most common driver of revision surgery in 2023 is infection, accounting for 32.5% of all revision total knee arthroplasties according to the AJRR 2024 Annual Report — a finding that underscores why infection prevention remains the single most critical focus area in post-operative care. From a patient perspective, the overall outlook remains positive: the 10-year revision rate for cemented TKA is only 2.13%, and one large NIH-backed cohort study reported a 96.8% survival rate at 20 years for total knee arthroplasty. The gap between these reassuring individual-level statistics and the dramatic system-level projections is explained by the sheer and growing scale of total knee replacement volume — when over a million procedures are eventually being performed annually, even a small revision percentage generates enormous absolute numbers of patients who need follow-up surgical care.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
